Table 1: General information of the transplanted patients studied.
|
Patients characteristics |
Total patients n = 236 (100%) |
Liver recipients n = 74 (100%) |
Kidney recipients n = 109 (100%) |
Bone marrow recipients n = 53 ≠ (100%) |
||||||
|
|
Pediatric 48 (100%) |
Adults 188 (100%) |
Pediatric 30 (100%) |
Adults 44 (100%) |
Pediatric 13 (100%) |
Adults 96 (100%) |
Pediatric 5 (100%) |
Adults 48 (100%) |
||
|
Donor*
|
Live (n = 66) |
11 (22.9) |
55 (29.2) |
5 (16.7) |
0 (0.0) |
1 (7.7) |
7 (7.3) |
5 (100.0) |
48 (100.0) |
|
|
Deceased (n = 170) |
37 (77.1) |
133 (70.7) |
25 (83.3) |
44 (100.0) |
12 (92.3) |
89 (92.7) |
0 (0.0) |
0 (0.0) |
||
|
Age average (range) |
10.4 (1-17) |
42.9 (19-68) |
9.8 (1-17) |
47.5 (20-68) |
12.8 (7-16) |
41.7 (24-64) |
7.8 (3-17) |
40.6 (19-58) |
||
|
Female sex (n = 113) |
29 (60.4) |
84 (44.7) |
19 (63.3) |
25 (56.7) |
7 (53.8) |
35 (36.5) |
3 (60.0) |
24 (50.0) |
||
|
Total of CMV IgG Pre-transplant serology performed (n = 155) |
n = 39 35 (89.7) |
n = 116 104 (89.6) |
n = 23 21 (91.3) |
n = 32 30 (93.7) |
n = 11 10 (90.9) |
n = 45 40 (88.9) |
n = 5 4 (80) |
n = 39 34 (87.2) |
||
|
Total of EBV IgG Pre-transplant serology performed (n = 155) |
n = 39 35 (89.7) |
n = 116 112 (96.5) |
n = 23 22 (95.6) |
n = 32 31 (96.9) |
n = 11 9 (81.8) |
n = 45 43 (95.6) |
n = 5 4 (80) |
n = 39 38 (97.4) |
||
|
Total of HSV IgG Pre-transplant serology performed (n = 155) |
n = 39 31 (79.5) |
n = 116 109 (94.0) |
n = 23 19 (82.6%) |
n = 32 30 (93.7) |
n = 11 8 (72.7) |
n = 45 42 (93.3) |
n = 5 4 (80) |
n = 39 37 (94.9) |
||
|
Immunosuppression regimen (%) |
|
|||||||||
|
Methilprednisolone |
48 (100) |
138 (73.4) |
30 (100) |
44 (100.0) |
13 (100) |
82 (85.4) |
5 (100.0) |
12 (25.0) |
||
|
Cyclosporine (Cs) |
26 (54.2) |
116 (61.7) |
16 (53.3) |
36 (81.8) |
8 (61.5) |
66 (68.8) |
4 (80.0) |
14 (29.2) |
||
|
Tacrolimus |
17 (35.4) |
8 (4.2) |
14 (46.7) |
8 (18.2) |
3 (23.1) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
||
|
Mycophenolate mofetil (MMF) |
36 (75) |
82 (43.7) |
27 (90) |
29 (65.9) |
8 (61.5) |
50 (52.1) |
1 (20.0) |
3 (6.3) |
||
|
Basiliximab |
10 (20.8) |
0 (0.00) |
5 (16.7) |
0 (0.0) |
5 (38.4) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
||
|
Thimogan |
5 (10.4) |
4 (2.1) |
0 (0.0) |
4 (9.1) |
5 (38.4) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
||
|
Radiation |
3 (6.2) |
24 (12.8) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
3 (60.0) |
24 (50.0) |
||
|
Methotrexate |
3 (6.2) |
16 (8.5) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
3 (60.0) |
16 (33.3) |
||
|
Cyclophosphamide |
4 (8.3) |
16 (8.5) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
4 (80.0) |
16 (33.3) |
||
|
Antiviral prophylaxis (time after the graft) |
|
|||||||||
|
GCV/VGCV |
44 (91.7) |
4 (2.1) |
30 (100.0) (1 month) |
0 (0.0) |
13 (100.0) (3 months) |
2 (2.1) (1 month) |
1 (20.0) (2 months) |
2 (4.2) (1 month) |
||
|
ACV |
34 (70.8) |
37 (19.7) |
30 (100.0) (2 months after GCV) |
0 (0.0) |
0 (0.0) |
0 (0.0) |
4 (80.0) (1 month) |
37 (77.1) (1 month) |
||
|
Graft loss only (n = 9) |
4 (8.3) |
5 (2.7) |
1 (3.3) |
0 (0.0) |
3 (23.1) |
4 (4.2) |
0 (0.0) |
1 (2.1) |
||
|
Died (n = 26) |
7 (14.6) |
19 (10.1) |
3 (10.0) |
9 (20.4) |
2 (15.4) |
6 (6.2) |
2 (40.0) |
4 (8.3) |
||
|
Successful transplant (n = 201) |
37 (77.1) |
164 (87.2) |
26 (86.7) |
35 (79.5) |
8 (61.5) |
86 (89.6) |
3 (60.0) |
43 (89.6) |
||
|
Samples analyzed {serum/urine} 3872** {1934/1934} |
938** {469/469} |
2934** {1467/1467} |
518** {259/259} |
742** {371/371} |
352** {176/176} |
1700** {850/850} |
68** {34/34} |
492** {246/246} |
||
Abbreviation: IgG: Immunoglobulin G; CMV: Cytomegalovirus; EBV: Epstein-Barr virus; HSV: Herpes Simplex virus; ACV: Acyclovir, GCV: Ganciclovir; VGCV: Valganciclovir.
*Only five out of the all donors were seronegatives to CMV, EBV or HSV IgG (Two seronegatives to CMV, one seronegative to HSV, one to EBV and one to CMV/HSV, they were match with seronegative recipients); **Patients who died or lost the graft had incomplete follow up. Additionally, 47 patients had an incomplete follow up (only 6 samples each); ≠36 autologous, one pediatric and 35 adults.